Hoyoung M. Maeng, M.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10, Room 3B37
- Bethesda, MD 20892
- 240-781-3253
- 301-480-4983
- hoyoung.maeng@nih.gov
RESEARCH SUMMARY
Dr. Maeng’s research focuses on harnessing the immune system to prevent and treat cancer. She believes that the essence of the NIH is "bench-to-bedside and back" exemplified by the clinical trials at the NIH Clinical Center. She is deeply involved in translating the preclinical findings into first-in-human clinical trials using cancer vaccines and other immune-modulatory agents.
Areas of Expertise
Information for Patients
Learn more about our clinical trials and the highly specialized care teams that lead them.
Research
Dr. Maeng's clinical research involves vaccines to harness one's own immune system to prevent and treat cancer including cancers associated with viral infections or hereditary cancer syndromes. She leads the effort in exploring various strategies to broaden cancer treatment options with lower toxicity and improved efficacy at the Vaccine Branch.
Publications
Cancer vaccines: translation from mice to human clinical trials
Cancer Vaccines-Translational Strategies.
Cancer Vaccines
Strategies for developing and optimizing cancer vaccines.
Biography
Hoyoung M. Maeng, M.D.
Dr. Maeng graduated from Yonsei University College of Medicine, Seoul, South Korea. She started her first research project at the Yonsei Cancer Center as a medical student where she first developed an interest in translational medicine. She completed her residency in internal medicine followed by a fellowship in hematology and oncology at Severance Hospital, Yonsei University. Further training at the Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center as a research fellow in 2005 provided her with a deeper insight into the understanding of viral oncoprotein and cancer. Based on the work done at that time, she was awarded the AACR-MedImmune Fellowship in 2007. After serving at the hospital operated by the National Insurance Corporation of the Korean government as a malignant hematology specialist, she returned to the U.S. to pursue a career as a translational researcher. She then completed her leukemia fellowship at the University of Texas MD Anderson Cancer Center, followed by further training in medical oncology at the NIH Hematology/Oncology Fellowship.
